Family Med Medical News about premature ejaculation; paroxetine

Become a Member Today!
Register

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Acceptance of and Discontinuation Rate from Paroxetine Treatment in Patients with Lifelong Premature Ejaculation
The Journal of Sexual Medicine, 07/31/09

Salonia A et al. – Thirty percent of lifelong PE patients seeking medical treatment for complaints of early ejaculation freely decided not to start any paroxetine treatment, and roughly 30% of patients who started therapy eventually discontinued it.

Methods

The authors analyzed the acceptance of and discontinuation rates of 93 consecutive potent patients (mean age, 37.6 years) seeking medical treatment for lifelong PE.
The patients received a paroxetine prescription (10 mg daily for 21 days and then 20 mg as needed) for the first 3 months. Thereafter, the patients could either stay with the same on–demand treatment or take paroxetine 10 mg daily for 3 months.
The patients were evaluated at 3 and 6 months

Results

Twenty–eight (30.10%) patients decided not to start paroxetine. Fear of using an "antidepressant drug" was the main reason (42.9%) for treatment nonacceptance.
Twenty (30.8%) patients who initiated therapy eventually discontinued it.
Treatment effect below expectations was the main reason of treatment dropout (75%) during the first 3 months, followed by temporary loss of interest in sex because of relationship issues (15%) and side effects (10%).
Of the patients who continued treatment, 77.8% preferred daily paroxetine, while 22.2% continued as–needed therapy.

<< Previous
Female Urinary Incontinence During Sexual Intercourse (Coital...

Next >>
Psychological distress in long-term survivors of adult-onset...